Interesting Images18F-Florbetapir PET in Primary Cerebral AmyloidomaSoffers, Frederik MD∗; Ceyssens, Sarah MD∗; Buffet, Wendi MD†; de Surgeloose, Didier MD‡; Crols, Roeland MD§Author Information From the ∗Department of Nuclear Medicine, University Hospital of Antwerp Departments of †Pathology ‡Radiology §Neurology, Hospital Network Antwerp (ZNA), Antwerp, Belgium. Received for publication February 18, 2020; revision accepted June 7, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Frederik Soffers, MD, Department of Nuclear Medicine, University Hospital of Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium. E-mail: Frederik.Soffers@uza.be. Clinical Nuclear Medicine: October 2020 - Volume 45 - Issue 10 - p 838-839 doi: 10.1097/RLU.0000000000003214 Buy Metrics Abstract Amyloid deposition can lead to Alzheimer disease and cerebral amyloid angiopathy. Rarely, it presents as a solitary focal deposition, primary cerebral amyloidoma, which can be misinterpreted as a neoplasm because of the “tumor-like” appearances. We present the case of a 54-year-old woman where MRI revealed a T2-hyperintense mass periventricular in the white matter with moderate contrast enhancement. Pathological investigation revealed AL (lambda) amyloidoma. 18F-florbetapir PET/CT was used to support the diagnosis and in follow-up. This case highlights that 18F-florbetapir PET/CT might play a role in the diagnostic workup of patients suggestive of cerebral amyloidoma, especially in cases where biopsy is not feasible. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.